Gennova Biopharmaceuticals Limited

Gennova Biopharmaceuticals Ltd., headquartered in Pune, India, is a technology-driven biotechnology company focused on developing, producing, and commercializing innovative biotherapeutics to combat life-threatening diseases. Guided by a mission to deliver efficient, effective, and accessible healthcare solutions, Gennova is redefining the future of healthcare through its commitment to scientific excellence and innovation. By leveraging cutting-edge technologies in biotherapeutics and vaccines, the company is making transformative breakthroughs more accessible to diverse populations around the world.

Gennova’s therapeutic expertise spans cardiovascular, neurology, nephrology, oncology, and ophthalmology, with focused efforts underway in emerging areas such as personalized mRNA vaccines for cancer. Incorporating state-of-the-art biomanufacturing practices, the company produces its recombinant products using bacterial, mammalian, and mRNA-based expression platforms, and has developed deep capabilities in perfusion-based continuous manufacturing technologies. Gennova has successfully commercialized nine products, including biosimilars, generics, and vaccines.

Through innovation-driven biomanufacturing, Gennova became the first biotechnology company in India to launch a biosimilar of the third-generation thrombolytic protein, tenecteplase, initially addressing unmet needs in cardiovascular care. Building on this pioneering work, Gennova developed and launched TENECTASE®, which became the first third-generation thrombolytic globally approved for Acute Ischemic Stroke (AIS). This breakthrough innovation was recognized by the Department of Biotechnology (DBT), Government of India, with the prestigious Biotech Product, Process Development and Commercialization Award 2019, and is now part of the Ministry of Health and Family Welfare’s national guidelines for emergency stroke management (Prevention and Management of Stroke, 2019; updated 2024).

In the oncology space, Gennova has leveraged its expertise in high cell density fermentation and advanced genetic manipulation to develop and commercialize filgrastim and its long-acting counterpart, PEG-filgrastim. Additionally, through continued innovation in pegylation processes, Gennova became the first Indian company to develop and launch a generic pegaspargase, HAMSYL®, in 2014. This critical therapy for acute lymphoblastic leukemia (ALL) was developed at the request of Tata Memorial Hospital, Mumbai, to address a gap in treatment options for this orphan indication.

Gennova is also a pioneer in mRNA technology, having introduced India’s first mRNA vaccines and the world’s first thermostable mRNA vaccines for COVID-19 — GEMCOVAC®-19 and GEMCOVAC®-OM. These advances significantly enhanced pandemic preparedness and demonstrated the versatility of Gennova’s mRNA platform, which is now being applied to diseases such as tuberculosis, Nipah virus, and rabies.

From bench to bedside, Gennova integrates deep research capabilities with advanced process controls. Artificial intelligence and machine learning are employed to build cognitive models that optimize biomanufacturing processes, ensuring precision, regulatory compliance, and cost-effectiveness. Backed by a multidisciplinary team of scientists and technocrats, Gennova’s integrated strengths across R&D, regulatory science, clinical development, and business strategy have positioned it as a leader in India’s biopharmaceutical landscape.

Today, Gennova stands at the forefront of global innovation — taking Indian science to the world, advancing next-generation healthcare technologies, and earning recognition as a trusted name in biotherapeutics.